A Missing Link in Cancer Clinical Trials: Diverse Populations

Clinical trials for new cancer treatments are most effective when a diverse group of patients participates. Michigan Medicine wants more patients to get involved.

7:00 AM

Author | Kevin Joy

 

Cancer affects everyone, no matter their background or ethnicity.

Yet cancer clinical trials — research studies designed to test the safety and effectiveness of potential new treatments — don't always represent the full scope of the population.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

That's because there is a shortage of diverse clinical trial participants, a deficit that can affect efforts to treat and cure the disease in all patients, no matter their gender, race or ethnicity.

"When we study certain conditions, certain cancers, and we only use one population, we find out a lot about that population," says John M. Carethers, M.D., chair of internal medicine at Michigan Medicine, "but it says nothing about other populations."

For clinical trials to be most effective, diversity is key. Certain types of cancer are more prevalent in black or Hispanic Americans; some cancers behave differently in younger versus older people.

Increasing the number of people involved means researchers could get a clearer handle on how best to help everyone.

Some clinical trials involve comparing two types of treatment or trying a new use for a drug already approved by the Food and Drug Administration for a different cancer. Others involve drugs that are being administered to people for the first time after rigorous laboratory testing.

Each method can help researchers determine if a medication works more effectively than the current standard treatments.

Still, "we won't know until we compare it head-to-head," says Lori Pierce, M.D., a Michigan Medicine radiation oncologist.

SEE ALSO: How Clinical Trials Helped Three Cancer Patients Thrive

She and Carethers know that most patients might have questions about clinical trials.

They also acknowledge that minorities could have particular concerns in light of the Tuskegee syphilis experiment, a federally funded — and highly unethical — study that for 40 years only monitored hundreds of black men with syphilis despite the availability of treatment.

Such wrongdoing, the clinicians stress, is well in the past: "Everyone wants to be cured of their disease," Pierce says. "Clinical trials give everyone equal opportunity to do so."

To learn more about clinical trials at Michigan Medicine, call the Cancer AnswerLine at 1-800-865-1125. 


More Articles About: Cancer Care Cancer Research Health Care Delivery, Policy and Economics Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories
Health Lab
Survivor in Action: A Cancer Patient Lends Her Mind, Body and Voice to Help Others
Participation in clinical trials is one way a mother fights back against cancer. She also volunteers with cancer patients and is working to boost research funds to study her own disease.
green background with white drawing of doctor at patient beside having conversation
Health Lab
Have a seat, doctor: Study suggests eye level connection makes a difference in hospitals
When doctors sit at hospitalized patients’ bedsides, it can have a more positive impact than if they stand, a review of data suggests – but a new study seeks to find out for sure.
blue purple cell dots on white background all over in different patterns
Health Lab
Research finds possible therapies to target oncogenic transcription factors in multiple cancer types
A study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.
iv chemo bags
Health Lab
Drug-chemo combo increases cancer treatment efficacy
A study finds giving a fatty acid inhibitor alongside chemotherapy could improve the treatment efficacy for patients with brain metastases from triple negative breast cancer
close up photo of yellow pills lined up on a bright blue matt
Health Lab
New drug candidate blocks resistance to cancer therapies
A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance.
two women, one older one younger, looking concerned listening to a provider across from them with back to camera
Health Lab
Many breast cancer survivors don't receive genetic testing, despite being eligible
As cancer treatment and survivorship care relies more on understanding the genetic make up of an individual’s tumor, a study from the University of Michigan Health Rogel Cancer Center finds that many breast cancer survivors who meet criteria for genetic counseling and testing are not receiving it.